Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allisartan medoxomil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Next Previous
X
Search
Drug Profile

Allisartan medoxomil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Alternative Names: SAL-0108

Latest Information Update: 13 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Cardiovascular therapies; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 05 Sep 2024 Efficacy and adverse events data from a phase III trial in Hypertension presented at the Hypertension Scientific Session 2024 (HTN-2024)
  • 27 May 2022 Phase-III clinical trials in Hypertension (In volunteers) in China (PO)
  • 21 Jun 2021 Preclinical trials in Hypertension in China (PO) before June 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top